SELLAS生命科学集团近日宣布，针对其核心候选药物galinpepimut-S（GPS）治疗急性髓系白血病（AML）的关键性三期REGAL试验取得最新进展。该试验旨在评估GPS在AML患者中的疗效与安全性，目前正在按计划推进患者入组与临床数据收集工作。此次更新标志着SELLAS在肿瘤免疫治疗领域的重要里程碑，为后续监管申报和商业化奠定基础。
SELLAS生命科学集团近日宣布，针对其核心候选药物galinpepimut-S（GPS）治疗急性髓系白血病（AML）的关键性三期REGAL试验取得最新进展。该试验旨在评估GPS在AML患者中的疗效与安全性，目前正在按计划推进患者入组与临床数据收集工作。此次更新标志着SELLAS在肿瘤免疫治疗领域的重要里程碑，为后续监管申报和商业化奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.